Boehringer Ingelheim was an early adopter of ... to be done remotely and directly from patients through digital devices like sensors, sponsor-provided devices, smartphones, and tablets ...

Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the oncology-focused platform company’s decision to file for bankruptcy. Notable's ...

The therapy is being co-developed with Boehringer Ingelheim as a smart device-based app and is intended to be used alongside drug treatment for schizophrenia, and is one of several DTx apps the ...

Find out why Boehringer, Amgen and Novartis have been awarded the highest reputation scores by several cardiovascular patient ...

The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...

INGELHEIM, Germany & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Boehringer Ingelheim and Circle Pharma (Circle) announce a new research collaboration and license agreement with the shared goal ...

A new survey shows that three Big Pharmas have stolen the hearts of patient groups representing nearly 1 million people with cardiovascular conditions. | A new survey shows that three Big Pharmas have ...

Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for survodutide (BI 456906), a dual glucagon/GLP-1 receptor agonist 2 ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare ...

Boehringer Ingelheim Animal Health is working on first-in-class innovation for the prediction, prevention, and treatment of diseases in animals. For veterinarians, pet owners, producers ...

Abdulla also aims to further strengthen relationships with regional governments and key healthcare stakeholders to ensure sustainable patient access to Boehringer Ingelheim’s portfolio of leading ...